(Q40693199)

English

Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial

scientific article published on 26 April 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

0 references

1 reference

based on heuristic

inferred from title

Jonathan Corren

3

object named as

Jonathan Corren

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

author name string

Sally Wenzel

1

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Mario Castro

2

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Jorge Maspero

4

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Lin Wang

5

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Bingzhi Zhang

6

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Gianluca Pirozzi

7

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

E Rand Sutherland

8

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Robert R Evans

9

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Vijay N Joish

10

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Laurent Eckert

11

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Neil M H Graham

12

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Neil Stahl

13

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

George D Yancopoulos

14

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Mariana Louis-Tisserand

15

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Ariel Teper

16

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

language of work or name

0 references

publication date

26 April 2016

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

388

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

10039

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

31-44

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Uncontrolled asthma: a review of the prevalence, disease burden and options for treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930307-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Predicting asthma exacerbations in children

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930307-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Development and validation of a novel risk score for asthma exacerbations: The risk score for exacerbations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930307-5

7 January 2021

based on heuristic

inferred from DOI database lookup

International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930307-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930307-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Dupilumab in persistent asthma with elevated eosinophil levels

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930307-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Type 2 immunity is controlled by IL-4/IL-13 expression in hematopoietic non-eosinophil cells of the innate immune system

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930307-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Asthma and allergic inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930307-5

7 January 2021

based on heuristic

inferred from DOI database lookup

T-helper type 2-driven inflammation defines major subphenotypes of asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930307-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Lebrikizumab treatment in adults with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930307-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Targeting the interleukin pathway in the treatment of asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930307-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Type 2 inflammation in asthma--present in most, absent in many

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930307-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Targeting key proximal drivers of type 2 inflammation in disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930307-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930307-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Dupilumab treatment in adults with moderate-to-severe atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930307-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930307-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Self-reported lifetime prevalence of atopic dermatitis and co-morbidity with asthma and eczema in adulthood: a population-based cross-sectional survey

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930307-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis: A Randomized Clinical Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930307-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Measurement properties and interpretation of three shortened versions of the asthma control questionnaire

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930307-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930307-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Determining a minimal important change in a disease-specific Quality of Life Questionnaire.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930307-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930307-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Omalizumab in asthma: an update on recent developments

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930307-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930307-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Omalizumab for asthma in adults and children

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930307-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930307-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Mepolizumab treatment in patients with severe eosinophilic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930307-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930307-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(16)30307-5

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40693199&oldid=2188962316"